12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MLN9708: Phase III started

Takeda's Millennium Pharmaceuticals Inc. subsidiary began the open-label, international Phase III TOURMALINE-AL1 trial to compare 4 mg oral MLN9708 once weekly for the first 3 weeks of a 4-week cycle until disease progression plus...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >